GammaDelta Therapeutics is a UK headquartered biotechnology company founded upon world-class academic research conducted by Professor Adrian Hayday and Dr Oliver Nussbaumer, at King’s College London and the Francis Crick Institute and supported by Cancer Research Technology.
GammaDelta Therapeutics aims to harness the unique properties of γδ T cells to improve patient outcomes and survival rates among patients with haematological malignancies and solid tumours.
Our mission is to deliver highly effective allogeneic immunotherapies based on the unique properties of Vδ1+ T cells with potential to provide additional benefits towards patient survival in the treatment of cancers. Our proprietary isolation and expansion protocols have the ability to selectively generate Vδ1+ T cell populations suitable for clinical application.
The Company’s technologies are based upon pioneering world-class research conducted by Professor Adrian Hayday and Dr Oliver Nussbaumer, at King’s College London and the Francis Crick Institute, and Professor Bruno Silva-Santos at the University of Lisbon.
GammaDelta’s technology has been recognised for its therapeutic potential, attracting interest from the pharmaceutical industry and investment from Takeda Pharmaceutical Company Limited and Abingworth LLP.
GammaDelta Therapeutics aims to harness the unique properties of γδ T cells to improve patient outcomes and survival rates among patients with haematological malignancies and solid tumours.
Our mission is to deliver highly effective allogeneic immunotherapies based on the unique properties of Vδ1+ T cells with potential to provide additional benefits towards patient survival in the treatment of cancers. Our proprietary isolation and expansion protocols have the ability to selectively generate Vδ1+ T cell populations suitable for clinical application.
The Company’s technologies are based upon pioneering world-class research conducted by Professor Adrian Hayday and Dr Oliver Nussbaumer, at King’s College London and the Francis Crick Institute, and Professor Bruno Silva-Santos at the University of Lisbon.
GammaDelta’s technology has been recognised for its therapeutic potential, attracting interest from the pharmaceutical industry and investment from Takeda Pharmaceutical Company Limited and Abingworth LLP.
Location: United Kingdom, England, London
Employees: 51-200
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
| - | Abingworth... | abingworth... |
Mentions in press and media 1
| Date | Title | Description |
| 20.05.2021 | GammaDelta Therapeutics receives FDA Clearance of IND Application for GDX012, a novel allogeneic variable delta 1 gamma-delta T cell cancer therapy | GammaDelta Therapeutics receives FDA Clearance of IND Application for GDX012, a novel allogeneic variable delta 1 gamma-delta T cell cancer therapy 20-05-2021 GammaDelta Therapeutics, a company focused on exploiting the unique properties of... |